In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue
Open Access
- 1 October 1998
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 78 (8) , 1024-1029
Abstract
We evaluated the protective ability of amifostine on peripheral blood mononuclear cell (PBMC)-derived colony-forming unit (CFU) and PB CD34+ cells which were previously exposed in vitro to etoposide, carboplatin, doxorubicin and taxotere. Amifostine pretreatment protected PBMC-derived CFU from the toxic effect of etoposide, carboplatin and taxotere. A significant detrimental effect was exerted by amifostine on the growth of doxorubicin-treated PBMC-derived CFU. Liquid cultures of PB CD34+ cells reproduced faithfully the effects observed on growth of PBMC-derived CFU and confirmed amifostine chemoprotection against etoposide and carboplatin with its detrimental effect on doxorubicin-treated progenitors. Combining the data of viable cell count, cytometric estimation of apoptosis, cell cycle and viable cell replication rate, we found that amifostine protects from etoposide and carboplatin toxicity mainly through a mechanism of cell rescue. Conversely, the detrimental effect of amifostine on the growth of doxorubicin-treated PB CD34+ cells is apparently due to an increased G2/M arrest. In conclusion, amifostine protects haematopoietic progenitors from etoposide, carboplatin and taxotere. Progenitor rescue is the mechanism through which amifostine reduced etoposide and carboplatin toxicity.Keywords
This publication has 26 references indexed in Scilit:
- Degradation of 2-(3-aminopropylamino)-ethanethiol (WR-1065) by Cu-dependent amine oxidases and influence on glutathione status of chinese hamster ovary cellsBiochemical Pharmacology, 1995
- Low-dose cyclophosphamide in combination with cisplatin or epirubicin plus rhG-CSF allows adequate collection of PBSC for autotransplantation during adjuvant therapy for high-risk cancer.1994
- Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support.1994
- Determination of lymphocyte division by flow cytometryJournal of Immunological Methods, 1994
- WR2721 as a modulator of cisplatin-and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approachCancer Chemotherapy and Pharmacology, 1993
- Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion.1993
- Evaluation of a Novel Automated Protocol for the Collection of Peripheral Blood Stem Cells Mobilized with Chemotherapy or Chemotherapy Plus G-CSF Using the Fresenius AS104 Cell SeparatorJournal of Hematotherapy, 1993
- Dose dependence of the cytokinetic and cytotoxic effects of epirubicin in vitroCancer Chemotherapy and Pharmacology, 1992
- Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cellsCell, 1991
- Differential Chemoprotection of Normal and Malignant Tissues23JNCI: Journal of the National Cancer Institute, 1969